Al-Azhar University Faculty of Medicine for Girls

The Inner Circle Acknowledges, Edsa Negussie as a Top Pinnacle Professional for her contributions to the field of Radiology

Retrieved on: 
Friday, September 15, 2023
Faculty, X-ray, CT, Radiation, University, American Board of Radiology, Education, American Board of Medical Specialties, Michigan State University College of Human Medicine, ABR, PET, Multimedia, University college, Mentorship, Obstetrics, World Medical Relief, Radiological Society of North America, Inner circle, Nuclear medicine, Medical specialty, American Board of Commissioners for Foreign Missions, Doctorate, MRI, Adrian Dixon, Doctor of Medicine, Magnetic resonance imaging, MD, Al-Azhar University Faculty of Medicine for Girls, Patient, Associate, Addis Ababa University, Ascension Providence Hospital, Novi Campus, Michigan State Medical Society, Liver, American College, Mammography, Society, Clinical, SPECT, Providence Hospital, Disease, Dentistry, Medical imaging, Nursing, Medicine, Radiology

BLOOMFIELD HILLS, Mich., Sept. 15, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Edsa Negussie is acknowledged as a Top Pinnacle Professional for her contributions to the field of Radiology.

Key Points: 
  • BLOOMFIELD HILLS, Mich., Sept. 15, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Edsa Negussie is acknowledged as a Top Pinnacle Professional for her contributions to the field of Radiology.
  • Dr. Negussie pursued higher education while in Ethiopia at Addis Ababa University where she received a Doctorate of Medicine from the Faculty of Medicine.
  • According to Dr. Negussie, diagnostic radiology is a medical specialty that employs non-invasive imaging modalities to diagnose patients.
  • According to Dr. Negussie, Southfield Radiology Associates provides comprehensive, personalized care with cutting-edge radiology technology.

GE HealthCare to Showcase Latest AI Innovations at HIMSS 2023

Retrieved on: 
Monday, April 17, 2023
Software, General Health, Radiology, Pharmaceutical, Data Management, Medical Devices, Technology, Artificial Intelligence, Health Technology, Cardiology, Biotechnology, Health, Quotient, MUSE, Table, McCormick Place, Al-Azhar University Faculty of Medicine for Girls, Point of care, HIT, ViewPoint, Hospital, MD, Patient, PHI, Digital, Wireless ambulatory ECG, GE HealthCare, Hit Like a Girl, New Method College, Wearable technology, Command center, ADT, MS, GM, Exhibition, Nursing, Obstetrics, FDA, Woman, Conference, Caregiver, Level 4, Workflow, GE, ECG, HIMSS, Alivecor, Ecosystem, EMR, Sale, Portrait, AM, Architecture, Healthcare Information and Management Systems Society, Vaccine, Medical imaging, Medical device, Nightclub, Ultrasound, Mothew v Bristol & West Building Society

“We are transforming healthcare by delivering advanced technology to improve patients care options, experience, and outcomes,” said Dr. Taha Kass-Hout, Chief Technology Officer, MD, MS, GE HealthCare.

Key Points: 
  • “We are transforming healthcare by delivering advanced technology to improve patients care options, experience, and outcomes,” said Dr. Taha Kass-Hout, Chief Technology Officer, MD, MS, GE HealthCare.
  • ReadySee Asset Management & Network Supervision Solution - GE HealthCare introduces a new asset management & network supervision solution, ReadySee.
  • Join us to show the power of the pack with an all-female led delegation mini tour starting and ending at the GE HealthCare booth (1712).
  • To learn more about GE HealthCare products at HIMSS, visit booth 1712 or the GE HealthCare HIMSS 2023 site .

Seegene unveils world's first commercialized '3 Ct' PCR assay

Retrieved on: 
Tuesday, April 26, 2022
Coinfection, DNA, Degenerative disease, DPO, Urinary tract infection, STI, Polymerase chain reaction, Al-Azhar University Faculty of Medicine for Girls, Cervical cancer, Life, European, Hospital, UTI, PCR, HPV, Infection, Technology, Genotype, Middle East respiratory syndrome, MDX, Faculty, Multimedia, Industry, University, University of Limoges, View, Congress, C-Lab, Medical imaging, Pharmaceutical industry, Medicine

In a polymerase chain reaction (PCR), the cycle threshold (Ct) value is used to quantify the concentration of a viral DNA sequence (the target).

Key Points: 
  • In a polymerase chain reaction (PCR), the cycle threshold (Ct) value is used to quantify the concentration of a viral DNA sequence (the target).
  • Due to technological limitations, the conventional real-time PCR technique finds the Ct value of one target in one channel.
  • But Seegene's '3 Ct' technology can provide the Ct value of three targets in one channel without compromising sensitivity and specificity.
  • Using five channels in a single tube, Seegene can provide quantitative data for a total of 15 targets.

Seegene unveils world's first commercialized '3 Ct' PCR assay

Retrieved on: 
Tuesday, April 26, 2022
Coinfection, DNA, Degenerative disease, DPO, Urinary tract infection, STI, Polymerase chain reaction, Al-Azhar University Faculty of Medicine for Girls, Cervical cancer, Life, European, Hospital, UTI, PCR, HPV, Infection, Technology, Genotype, Middle East respiratory syndrome, MDX, Faculty, Industry, University, University of Limoges, Congress, C-Lab, Medical imaging, Pharmaceutical industry, Medicine

In a polymerase chain reaction (PCR), the cycle threshold (Ct) value is used to quantify the concentration of a viral DNA sequence (the target).

Key Points: 
  • In a polymerase chain reaction (PCR), the cycle threshold (Ct) value is used to quantify the concentration of a viral DNA sequence (the target).
  • Due to technological limitations, the conventional real-time PCR technique finds the Ct value of one target in one channel.
  • Using five channels in a single tube, Seegene can provide quantitative data for a total of 15 targets.
  • "Seegene is a company very involved in the development of molecular diagnostics tests for the detection of different pathogens.

Provectus Biopharmaceuticals Announces Presentation of Full Study Data from Metastatic Neuroendocrine Cancer Phase 1 Trial of PV-10® at European Society for Medical Oncology (ESMO) Congress 2021

Retrieved on: 
Tuesday, September 21, 2021
MBBS, The Queen Elizabeth Hospital, Adelaide, Clinical trial, Al-Azhar University Faculty of Medicine for Girls, INCA, Oncology, Wilms' tumor, Liver disease, Review, Neoplasm, OTCQB, Diagnosis, NET, National, Skin, Patient, Medical school, Congress, Hematology, IL, CT, SSAS, Immunogenic cell death, University, European Society for Medical Oncology, Adult, RECIST, Immunotherapy, Somatostatin, Company, Legislation, Mnet, Faculty, ORR, PRRT, Medicine, Liver, Injection, NIH, Safety, ESMO, Forward-looking statement, Data collection, SSA, GLOBE, Pharmaceutical industry, Medical imaging

We look forward to seeing PV-10s future use in this refractory setting, and also in Phase 2 combination therapy testing for earlier lines of neuroendocrine cancer treatment.

Key Points: 
  • We look forward to seeing PV-10s future use in this refractory setting, and also in Phase 2 combination therapy testing for earlier lines of neuroendocrine cancer treatment.
  • Our clinical trial database should lock in the fourth quarter of 2021, providing us the opportunity to finalize data collection and analysis prior to assessing PV-10s regulatory prospects and options.
  • Six patients in the first cohort each received one percutaneously-administered injection of PV-10 to one target lesion per treatment cycle.
  • Due to the risks, uncertainties, and assumptions inherent in forward-looking statements, readers should not place undue reliance on these forward-looking statements.